For patients with stage IIB and III cancer, a significant better survival was observed with higher CD4+ (DFS, P=0.0155; OS, P=0.0121) signals in the tumor region, and CD3+ (DFS, P=0.0110; OS, P=0.0100) and CD8+ (DFS, P=0.0420; OS, P=0.0809) signals in the IM, which is shown in Table 4. Here, CD8A is linked to cancer.